③维持治疗并非标准AML治疗组成。 (2)异基因HCT ①适应症:遗传学良好AML第一次CR后并不优先行异基因HCT;异基因HCT推荐用于复发风险>35%-40%的AML;不良遗传学AML获得CR后应尽早移植;异基因HCT是原发耐药AML的唯一治愈方法;患者没有MRD或是不良遗传学改变,且...
③维持治疗并非标准AML治疗组成。 (2)异基因HCT ①适应症:遗传学良好AML第一次CR后并不优先行异基因HCT;异基因HCT推荐用于复发风险>35%-40%的AML;不良遗传学AML获得CR后应尽早移植;异基因HCT是原发耐药AML的唯一治愈方法;患者没有MRD或是不良遗传学改变,且高危发生非复发死亡(NRM)时应接受化疗或自体HCT。连续...
因此美国学者使用更新的 ELN 2022 指南在广泛表征的当代大型 AML 患者队列(n=513)中评估结局并与ELN 2017对比,证实ELN 2022 指南改善了接受强化诱导化疗(IC)AML患者的生存分层。研究结果近日发表于《Blood Advances》。 研究方法 本分析纳入2009.1.1日至...
出国看病资讯HSCT 前期 WT1 水平与 ELN 2017 风险分类是中度风险 AML 结局的更好预测指标 尽管欧洲白血病网2017年风险分层对于预测中等风险急性髓系白血病异基因造血干细胞移植后的结局无效,但移植前Wilms肿瘤基因1表达和FLT3-ITD突变显示出有希望的预测能力。——出国看病 欧洲白血病网2017(ELN 2017)风险分层分类似乎没...
Introduction Recently, genomic mutation profiling of leukemic cells has been actively studied and some results have been integrated into the 2017 ELN classification with cytogenetic analysis for risk assessment of AML populations.1 However, only a few mutations are well identified and included in the ...
The 2 transplant procedures performed almost equally in the ELN2017-IR group (2-year OS of 73.9% vs 70.8%; P = .5552). This post hoc analysis of the GIMEMA AML1310 trial confirms that the ELN2017 classification is able to accurately discriminate patients with different outcomes and who may...
The benefit of lomustine in nonadverse chromosomal aberrations was restricted to patients with RUNX1, ASXL1, TP53, and FLT3-ITDhigh/NPM1WT mutations in contrast to the intermediate and favorable ELN2017 patients. This post-hoc analysis identified a subgroup of fit elderly AML patients with ...
Introduction Nucleophosmin 1-mutations (NPM1) and internal tandem duplications in the FMS-like tyrosine kinase 3 receptor gene (FLT3-ITDs) are the most frequently detected molecular abnormalities in patients with AML and are used for risk assessment and stratification of post-remission therapy. In ...
The benefit of lomustine in nonadverse chromosomal aberrations was restricted to patients with RUNX1, ASXL1, TP53, and FLT3-ITDhigh/NPM1WT mutations in contrast to the intermediate and favorable ELN2017 patients. This post-hoc analysis identified a subgroup of fit elderly AML patients with ...
ObjectiveOverexpression of ABCG2 and CD200 has been independently associated with poor outcome in acute myeloid leukemia (AML). However, no data are available on the role of these two factors in patients with core-binding factor (CBF)-positive or FLT3-negative/NPM1-mutated cytogenetically normal...